top of page

Currently Recruiting Studies

ADNI-3

The Alzheimer’s Disease Neuroimaging Initiative,
also known as ADNI, is a historic study of brain
aging looking to help change the future. ADNI’s
unprecedented approach to research is intended
to encourage new investigation and to increase
the pace of discovery in the race to prevent,
treat and one day cure Alzheimer’s disease.
The Alzheimer's Disease Neuroimaging Initiative (ADNI-3) is a non-treatment study that is funded by the National Institute of Health (NIH). The overall goal of this project is to determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. Enrolled subjects will be between 55-90 (inclusive) years of age. This study will enroll subjects who currently have a diagnosis of Alzheimer’s disease (AD) or subjects who do not have a diagnosis of AD, but have significant memory concerns and are of minority decent.

​

For more information, please contact Dr. Raymundo Hernando at 845-398-5578 or Ms. Anne Schatz at 845-398-6594

The Triad Study-Avanir

The purpose of this study is to evaluate the safety and efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type. Alzheimer’s is a brain disease that destroys brain cells and causes problems with memory, thinking and behavior. Agitated behaviors such as irritability and restlessness, physical and verbal aggression, and pacing and wandering are major problems, can be difficult to manage, and can impact one's quality of life. This study includes subjects who meet a diagnosis for Alzheimer’s dementia and demonstrate symptoms of agitation.

​

For information about our participation in the Avanir study, contact Dr. Antero Sarreal at 845-398-6532 or at asarreal@nki.rfmh.org.

 Studies no longer Recruiting

TCAD*

The primary objective of this study is to evaluate the safety and efficacy of T-817MA as an adjunct therapy to donepezil (Aricept). In Alzheimer’s disease (AD) the formation of beta amyloid, which is thought to be related to the progression of Alzheimer’s disease, eventually results in neuronal cell malfunction and death. T-817MA is a compound that has a protective effect on neural cells and could potentially prevent the toxic effect of beta amyloid on neuronal cells. Therefore, this trial will assess the effect of T-817MA on disease progression (disease worsening).

​

For information about our participation in the TCAD study, contact Vita Pomara at 845-398-5582; vpomara@nki.rfmh.org.

For more detailed information about the study and study drug, please click here.

TauRx*

This is a clinical trial that is funded by TauRx Pharmaceuticals. The primary objective of this study is to evaluate the efficacy, safety, and tolerability of Leuco-methylthioninium bis(hydromethanesulfonate) [LMTM] in treating mild Alzheimer’s disease. LMTM, the investigational product, is believed to have the potential to confer benefits over existing treatments for AD due to its ability to affect the process of tau aggregation, which is responsible for the underlying neurofibrillary pathology of Alzheimer’s disease. The secondary objective is to evaluate the effect of LMTM on functional activities of daily living as well as on other aspects of Alzheimer’s disease, including cognition and mood. This study will enroll subjects with a diagnosis of Alzheimer’s disease and are ≤90 years of age at screening.

​

For information, contact Dr. Antero Sarreal at 1-800-521-8367, 845-398-6532 or 845-398-5582, or at asarreal@nki.rfmh.org.

For more detailed information about the study and study drug, please click here.

Merck*

These are clinical trials funded by Merck Pharmaceuticals. The purpose of these studies is to evaluate the safety and efficacy of MK8931 in the possible treatment of Alzheimer’s disease. MK8931 reduces the level of Abeta deposits in the brain, which is a small piece of protein that may be involved in causing Alzheimer’s Disease (AD). Accumulation of this particular protein, is also thought to be related to the progression of AD and begins well before the onset of AD dementia and probably even before any cognitive decline associated with AD. Therefore, these trials will also assess the effect of MK-8931 on disease progression (disease worsening).

​

Enrolling: One study is enrolling subjects with a diagnosis of prodromal Alzheimer’s disease, positive PET-Amyloid scan, and between ages 50 and 85 at screening. The second Merck study is focused on those diagnosed with mild to moderate AD, positive PET-Amyloid scan, and between ages 55 and 85.

​

For information about our participation in the Merck study, contact Ms. Chelsea Reichert at 845-398-5583 or at creichert@nki.rfmh.org.

For more detailed information about this study and study drug please click here.

The Generation Study-Novartis *

Accera*

The Nathan S. Kline Institute has launched a new Alzheimer’s prevention trial – the Generation Study - and is now actively recruiting participants. The Generation Study is part of the Alzheimer’s Prevention Initiative (API), an international collaborative led by the Banner Alzheimer’s Institute (BAI) to accelerate the evaluation of promising treatments. The five-year Generation Study will involve more than 1,300 cognitively healthy older adults, ages 60 to 75, who are at high risk of developing symptoms of Alzheimer’s because they inherited two copies of the e4 type of the apolipoprotein (APOE) gene, the major genetic risk factor for developing Alzheimer’s disease at older ages. The Nathan S. Kline Institute is one of the approximately 90 selected sites in North America, Europe and Australia. Locally, we hope to recruit 10 people into the Generation Study. The Generation Study will determine whether two investigational anti-amyloid compounds—an active immunotherapy and an oral medication—can prevent or delay the emergence of symptoms of Alzheimer’s of people involved in the study. The Generation Study is the first to incorporate genetic testing and counseling into the study screening process. It is among the API efforts intended to help find faster ways to test the range of promising treatments in other individuals who, based on their genetic background or biological features, are at increased risk for Alzheimer’s. To learn more about the trial, visit www.GenerationStudy.com.

​

For information about our participation in the Generation Study, please contact Dr. Sameh Nosir at 845-398-6533 or 845-398-5582 or email him at snosir@nki.rfmh.org .

This is a clinical trial that is funded by Accera Pharmaceuticals. The purpose of this study is to evaluate the safety and efficacy of AC-1204 in the treatment of Alzheimer’s disease. A similar product to AC-1204 called Axona, has already been tested by Accera in patients with memory problems, including Alzheimer's disease. People with Alzheimer’s disease can have difficulty using glucose in the brain, which serves as the primary source of energy. Another energy source that your brain can use in place of glucose is ketone bodies. This study will determine whether increasing ketone body levels with AC-1204, will improve test scores that measure memory and other mental skills in study participants with Alzheimer’s disease. This study will enroll subjects with a diagnosis of mild to moderate Alzheimer’s disease and 66-90 years of age (inclusive) at screening.

​

For information about our participation in the Accera study, contact Ms. Chelsea Reichert at 845-398-5583, or at creichert@nki.rfmh.org.

​

For more detailed information about the study and study drug please click here.

ADNI-2*

The Alzheimer's Disease Neuroimaging Initiative (ADNI-2) is a non-treatment study that is funded by the National Institute of Health (NIH). The overall goal of this project is to determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. Enrolled subjects will be between 55-90 (inclusive) years of age. This study will enroll subjects who currently have a diagnosis of Alzheimer’s disease (AD) or subjects who do not have a diagnosis of AD, but have significant memory concerns.

​

For more detailed information about the study, please click here.

bottom of page